<ul><li>Among ICICI Securities' coverage universe, Dr Reddy’s grew the fastest at 15.8% YoY driven by inlicensed brands, Sun Pharma at 13.6% YoY and Ajanta Pharma at 13.2% YoY.</li><li>The India business of the brokerage's coverage companies grew 10.2% YoY to Rs 207 billion in Q4 FY25 driven by better pricing, volumes and new launches.</li><li>Pharma Q4 Results Review indicates healthy traction in India, with post gRevlimid uncertainty looming, according to ICICI Securities.</li><li>Sun Pharma, Cipla, Torrent, Piramal Pharma, Akums, and Abbott India are among ICICI Securities' top picks in the Pharma Q4 Results Review.</li></ul>

Pharma Q4 Results Review — India Traction Healthy; Post gRevlimid Uncertainty Looms, Says ICICI Securities

Discover more